Friday, September 29, 2023


Biotechnology News Magazine

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Angel Yeast Co., Ltd (“Angel Yeast” or “Angel”), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardii Bld-3 (S. boulardii Bld-3), and an innovative production technology for the new product. The patented yeast probiotic is designed to treat diarrhea and strengthen healthy digestive and immune systems in children and adults.

Saccharomyces boulardii (S. boulardii) is a kind of probiotic that has been considered a crucial nutritional intervention in treating diarrhea. The new strain of yeast probiotic developed by Angel Nutrition & Health Technical Center, S. boulardii Bld-3, is another ground-breaking addition to the S. boulardii family that has been proven effective in speeding up recovery from acute diarrhea and is beneficial to intestinal health in the long term,” said Dr. Zhang Yan, CTO of Angel Nutritech, established in 1992 by Angel Yeast focusing on human nutrition & health to develop and supply featured finished products to global human care industries.

COVID-19 has prompted more people to pay attention to their health and an increased focus on precautionary measures and healthcare products that prevent diseases and support their immune systems. On Google Trends, the search queries “gut health” and “probiotic” have seen several spikes during the pandemic. For gastrointestinal healthcare, keyword searches related to probiotics also climbed to a record high this year, signaling increased recognition of its robust ability to restore and maintain a healthy digestive system for humans.

The use of S. boulardii for management of adult and children with diarrhea has been widely prescribed by doctors and gastroenterologists for decades and its efficacy for combating an array of gastrointestinal conditions is well documented in medical literature. A study published in the Chinese Journal of Pediatrics concludes that certain types of probiotics can reduce the severity and duration of diarrhea. Among them, Lactobacillus rhamnosus GG and S. boulardii are the two most effective probiotics for anti-diarrhea treatment.

Unlike Lactobacillus probiotics, Angel’s S. boulardii Bld-3 is developed using the low-temperature fluidized bed process. The company’s unique protection technology allows it to quickly form a dense yeast shell that encloses active yeast probiotics entrapped inside. This process strengthens the yeast’s resistance to gastric acid and bile salts, enabling it to be applied in a wide variety of end probiotic products.

Angel’s S. boulardii Bld-3 is a suitable ingredient for wide-ranging probiotic dietary supplements. Thanks to the larger size of yeast probiotics, which is ten times as big as that of Lactobacillus probiotics, they are more likely to form a space-occupying effect in the intestinal tract and are resistant to antibiotics.

One of the world’s largest suppliers of yeast derivatives, Angel Yeast has over three decades of experience in the development and production of yeast products. In addition to S. boulardii Bld-3, Angel Yeast also produces Saccharomyces cerevisiae probiotic and other extensive ranges of functional yeast ingredients, with several new products in the pipeline including Kluyveromyces marxianus. At present, probiotic products produced by Angel Yeast have been sold to Europe and North America.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine